Skip to content

K.-A. Kovar

2 papers in the library · 230 citations · publishing 1998-2005

Papers

Psychological Effects of (S)-Ketamine and N,N-Dimethyltryptamine (DMT): A Double-Blind, Cross-Over Study in Healthy Volunteers

Pharmacopsychiatry November 1, 2005 E. Gouzoulis-Mayfrank, K. Heekeren, A. Neukirch et al. 198 citations

Two classes of hallucinogenic drugs model different aspects of schizophrenia-like symptoms. In a double-blind crossover study, fifteen healthy volunteers received both the serotonin 5-HT2A agonist DMT and the glutamate NMDA antagonist (S)-ketamine. Nine subjects completed both sessions. DMT produced stronger positive symptoms resembling schizophrenia, such as formal thought disorder and inappropriate affect. (S)-ketamine produced stronger negative symptoms, attention deficits, body perception disturbances, and catatonia-like motor phenomena. The findings suggest neither drug model is overall superior; rather, each models distinct symptom profiles: DMT models paranoid-type psychoses, while (S)-ketamine models psychoses with prominent negative and catatonic features.

Chemistry and Pharmacology of Hallucinogens, Entactogens and Stimulants

Pharmacopsychiatry July 1, 1998 K.-A. Kovar 32 citations

Amphetamines, tryptamines, phencyclidines, tetrahydrocannabinol, and ecstasy-group substances are classified as stimulants, hallucinogens, and entactogens. Their effects and mechanisms in different neurotransmitter systems are described. Twenty-eight new compounds in the amphetamine and tryptamine series have been calculated to have hallucinogenic effects exceeding those of mescaline. The distinct metabolic pathways of MDMA (ecstasy) and MDE in humans may account for their individual effects.